Houston Onglyza Lawyer

Tragically, Onglyza has been associated with some severe complications, the worst of which can be potentially deadly. These side effects, which have spurred various FDA warnings and safety communications, include (but are not necessarily limited to):

• Pancreatitis – This swelling of the pancreas can lead to pancreatic cancer and possibly death if left untreated. In November 2011, the FDA required Bristol and AstraZeneca to include warnings on all Onglyza packaging regarding the risk of developing pancreatitis.² In 2013, researchers reported finding that taking Onglyza could double patients’ risk of developing acute pancreatitis.³
• Pancreatic cancer – In March 2013, the FDA issued a Safety Communication, explaining that it was investigating the possible link between Onglyza and an increased risk of developing “pre-cancerous cellular changes called pancreatic duct metaplasia.”⁴ The FDA has yet to report on the findings of this investigation.
• Severe joint pain – In August 2015, the FDA issued a Safety Communication, warning that Onglyza (and other DDP-4 inhibitors) “may cause join pain that can be severe and disabling.” At that time, the FDA did explain that a number of Onglyza patients had filed reports regarding “severe joint pain” with the Agency’s Adverse Event Reporting System.⁵
• Heart failure – A 2013 study found that Onglyza patients have a 27 percent elevated risk of heart failure (when compared to patients taking placebos).⁶ In 2014, the FDA initiated an investigation into the reported link between Onglyza use and heart failure. In April 2016, the FDA announced that it was requiring labeling changes to all Onglyza labeling and medication guides to warn about the elevated “risk of heart failure, particularly in patients who already have heart or kidney disease.”⁷

Many who have suffered serious Onglyza complications have already taken action against Bristol and AstraZeneca, filing lawsuits to hold these drug makers accountable for:

• The serious injuries and losses patients have reportedly suffered from Onglyza use
• The drug makers’ failures to warn the public about the severe and potentially deadly risks associated with Onglyza.

To date, multidistrict litigation (MDL) has not been ordered for Onglyza claims. However, some experts believe an MDL may soon be established as more Onglyza lawsuits are filed across the U.S.

Regardless of the MDL status, those with pending and new Onglyza claims can be eligible for financial recoveries that may include (but may not be limited to) compensation for:

• Past and future medical bills
• Lost earnings
• Pain and suffering
• Loss of consortium.

A dangerous drug lawyer at the Amaro Law Firm can you get on the path to recovery and justice if you or a loved one has been seriously harmed by Onglyza.

Call (713) 352-7975, text (281) 612-8024, or contact our firm for your FREE consultation and essential insights regarding your potential claim.

At the Amaro Law Firm, our attorneys have more than 20 years’ experience representing injured patients – as well as families who have lost loved ones to fatal injuries – in dangerous drug cases, including those related to Onglyza.

Our proven record of success and excellence in dangerous drug claims is backed up by glowing testimonials from our former clients and our 5-star ratings on Google and Facebook.

________________________________________________________________________________

1: FDA Approval of Onglyza
2: FDA Label Changes Regarding Onglyza & Pancreatitis
3: 2013 Study on Onglyza & Acute Pancreatitis
4: 2013 FDA Announcement about Onglyza & Pancreatic Cancer Risk
5: 2015 FDA Announcement about Onglyza & Severe Joint Pain
6: According to the SAVOR-TIMI 53 Study
7: 2016 FDA Announcement about Onglyza & Heart Failure